1-20 of 35
Sebastian Böttcher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

B-cell Acute Lymphoblastic Leukemia in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide

Moritz Fürstenau, Anna Maria Fink, Anke Schilhabel, Jonathan Weiss, Sandra Robrecht, Robert Eckert, Javier de la Serna, Marta Crespo, Marta Coscia, Candida Vitale, Sebastian Böttcher, Gesche Weppner, Matthias Ritgen, Stephan Stilgenbauer, Eugen Tausch, Kirsten Fischer, Michael Hallek, Barbara Eichhorst, Monika Brüggemann, Carmen Diana Herling
Journal: Blood
Blood blood.2020008609.
DOI: https://doi.org/10.1182/blood.2020008609
Published: 2020
Includes: Supplemental data
Journal Articles

Severe Infections in Patients with Chronic Lymphocytic Leukemia Treated with (Immuno-)Chemotherapy: A Pooled Analysis of Gcllsg Trials

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Anna-Maria Fink, MD, Paula Cramer, Carmen D. Herling, MD PhD, Julia Von Tresckow, MD, Elisabeth Lange, MD, Sebastian Böttcher, MD PhD, Michael G. Kiehl, MD PhD, Martin Dreyling, MD, Ulrich Jaeger, Michael Gregor, MD, Ursula Vehling-Kaiser, MD, Matthias Ritgen, MD, Jan Dürig, MD, Eugen Tausch, MD, Stephan Stilgenbauer, MD, Clemens-Martin Wendtner, MD, Kirsten Fischer, MD, Valentin Goede, MD, Michael Hallek, MD, Barbara Eichhorst, MD, Petra Langerbeins, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
DOI: https://doi.org/10.1182/blood-2020-139242
Published: 2020
Journal Articles

BCR-Assosiated Kinase Inhibition in Relapsed/Refractory Chronic Lymphocytic Leukemia. Real World Experiences of a German Regional Clinical Register

Dietrich Kaempfe, MD, Roshanak Bob, MD, Joerg Brenn, Thomas Haverkamp, MD, Agnes Knopp, MD, Harald Stein, MD PhD Dr. h.c., Sebastian Böttcher, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11.
DOI: https://doi.org/10.1182/blood-2020-134686
Published: 2020
Journal Articles

Sequential Treatment with Bendamustine, Obinutuzumab (GA101) and Ibrutinib in Chronic Lymphocytic Leukemia (CLL): Final Results of the CLL2-BIG Trial of the German CLL Study Group (GCLLSG)

Julia Von Tresckow, Paula Cramer, Nisha De Silva, MBBS, MRCP, FRCPath, Jasmin Bahlo, PhD, Sandra Robrecht, PhD, Petra Langerbeins, MD, Anna- Maria Fink, MD, Othman Al-Sawaf, MD, Moritz Fürstenau, MD, Thomas Illmer, MD, Holger Klaproth, Eugen Tausch, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD, Sebastian Böttcher, MD, Barbara F. Eichhorst, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3046.
DOI: https://doi.org/10.1182/blood-2019-125895
Published: 2019
Journal Articles

Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group

Anna Maria Fink, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Michael Kneba, MD PhD, Eugen Tausch, Stephan Stilgenbauer, MD, Matthias Ritgen, MD, Sebastian Böttcher, MD, Kirsten Fischer, MD, Michael Hallek, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3040.
DOI: https://doi.org/10.1182/blood-2019-125063
Published: 2019
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
DOI: https://doi.org/10.1182/blood-2019-125825
Published: 2019
Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Clinical Trials & Observations
Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen
Journal: Blood
Blood (2019) 133 (5): 494–497.
DOI: https://doi.org/10.1182/blood-2018-03-839688
Published: 2019
Includes: Supplemental data
Journal Articles

Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia

William G. Wierda, MD PhD, Andrew W. Roberts, MBBS, PhD, Paolo Ghia, MD PhD, Jennifer R. Brown, MD PhD, Stephan Stilgenbauer, Florence Cymbalista, MD, Nicole Lamanna, MD, John F. Seymour, MBBS, PhD, Sebastian Böttcher, MD, Madlaina Breuleux, PhD DAS, Brenda Chyla, Lang Zhou, PhD, Jacqueline Nielsen, PhD, Su Young Kim, MD PhD, Jalaja Potluri, MD, Johnathan C. Maher, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath
Journal: Blood
Blood (2018) 132 (Supplement 1): 3134.
DOI: https://doi.org/10.1182/blood-2018-99-110183
Published: 2018
Journal Articles

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Sebastian Böttcher, Javier De la Serna, Julio Delgado, Franca Falzetti, Marco Gobbi, MD, Sandra Lejniece, Maria Chiara Di Bernardo, Navita L Mallalieu, Tina Nielsen, Andrea Knapp, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 4419.
DOI: https://doi.org/10.1182/blood-2018-99-118238
Published: 2018
Journal Articles

Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)

Moritz Fürstenau, MD, Jasmin Bahlo, PhD, Anna-Maria Fink, MD, Elisabeth Lange, Peter Dreger, MD, Martin Dreyling, MD PhD, Georg Hess, Matthias Ritgen, MD, Michael Kneba, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD, Clemens-Martin Wendtner, Valentin Goede, MD, Kirsten Fischer, MD, Sebastian Böttcher, Michael Hallek, Barbara Eichhorst
Journal: Blood
Blood (2018) 132 (Supplement 1): 4430.
DOI: https://doi.org/10.1182/blood-2018-99-113280
Published: 2018
Journal Articles

Real Life Dates of Chronic Lymphocytic Leukemia (CLL) in Germany. Interim Analysis of 234 Consecutively New Diagnosed Patients in a German Epidemiological-Clinical Register

Dietrich Kämpfe, MD, Harald Stein, MD PhD Dr. h.c., Roshanak Bob, MD, Sebastian Böttcher, Joerg Brenn, Agnes Knopp, MD, Thomas Haverkamp, MD, Christoph Schulte, MD, Detlef Haase, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2264.
DOI: https://doi.org/10.1182/blood-2018-99-110618
Published: 2018
Journal Articles

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Clinical Trials & Observations
Natalie Dimier, Paul Delmar, Carol Ward, Rodica Morariu-Zamfir, Günter Fingerle-Rowson, Jasmin Bahlo, Kirsten Fischer, Barbara Eichhorst, Valentin Goede, Jacques J. M. van Dongen, Matthias Ritgen, Sebastian Böttcher, Anton W. Langerak, Michael Kneba, Michael Hallek
Journal: Blood
Blood (2018) 131 (9): 955–962.
DOI: https://doi.org/10.1182/blood-2017-06-792333
Published: 2018
Includes: Supplemental data
Journal Articles

Prognostic Impact of Immunohistochemistry and MRD Results in Bone Marrow after Frontline Chemoimmunotherapy of Chronic Lymphocytic Leukemia (CLL): Results of Central Laboratory Analyses of the CLL10 Trial of the German CLL Study Group (GCLLSG)

Nadine Kutsch, MD, Sebastian Böttcher, MD PhD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, MD, Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, MD, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, MD, Torben Plesner, MD, Ilske Oschlies, MD, Marco Herling, MD PhD, Kirsten Fischer, MD, Hartmut Döhner, MD, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, MD PhD, Anna Maria Fink, MD, Michael Hallek, MD, Wolfram Klapper, MD, Barbara F. Eichhorst, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3021.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.3021.3021
Published: 2017
Journal Articles

Bendamustine Followed By Ofatumumab and Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): CLL2-BIO Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD, Julia von Tresckow, MD, Sandra Robrecht, PhD, Jasmin Bahlo, PhD, Othman Al-Sawaf, MD, Petra Langerbeins, MD, Werner Heinz, MD, Ursula Vehling-Kaiser, MD, Jan Dürig, MD, Eugen Tausch, MD, Manfred Hensel, MD, Anna-Maria Fink, MD, Kirsten Fischer, MD, Karl-Anton Kreuzer, MD, Sebastian Böttcher, MD PhD, Matthias Ritgen, Michael Kneba, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD PhD, Barbara F. Eichhorst, MD, Michael J. Hallek, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 494.
DOI: https://doi.org/10.1182/blood.V130.Suppl_1.494.494
Published: 2017
Journal Articles

Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial

Clinical Trials & Observations
Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Zeis, Michael Stadler, Jörg Bittenbring, Lutz Uharek, Christof Scheid, Ute Hegenbart, Anthony Ho, Michael Hallek, Michael Kneba, Norbert Schmitz, Hartmut Döhner, Peter Dreger
Journal: Blood
Blood (2017) 130 (12): 1477–1480.
DOI: https://doi.org/10.1182/blood-2017-04-775841
Published: 2017
Includes: Supplemental data
Journal Articles

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J. M. van Dongen, Sebastian Böttcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, Michael Hallek
Journal: Blood
Blood (2017) 129 (19): 2702–2705.
DOI: https://doi.org/10.1182/blood-2017-01-761973
Published: 2017
Includes: Supplemental data
Journal Articles

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

Brief Report
Friederike Braig, Anna Brandt, Mariele Goebeler, Hans-Peter Tony, Anna-Katharina Kurze, Peter Nollau, Thomas Bumm, Sebastian Böttcher, Ralf C. Bargou, Mascha Binder
Journal: Blood
Blood (2017) 129 (1): 100–104.
DOI: https://doi.org/10.1182/blood-2016-05-718395
Published: 2017
Includes: Supplemental data
Journal Articles

Favorable Toxicity Profile and Long Term Outcome of Elderly, but Physically Fit CLL Patients (pts) Receiving First Line Bendamustine and Rituximab (BR) Frontline Chemoimmunotherapy in Comparison to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Advanced Chronic Lymphocytic Leukemia (CLL): Update Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study)

Barbara F. Eichhorst, MD, Jasmin Bahlo, Christian Maurer, MD, Elisabeth Lange, MD, Hubert Köppler, Prof., Michael G Kiehl, MD, Martin Sökler, MD, Rudolf Schlag, Ursula Vehling-Kaiser, MD, Georg Köchling, MD, Christoph Plöger, MD, Michael Gregor, Torben Plesner, MD, Marco Herling, MD PhD, Kirsten Fischer, Hartmut Döhner, MD, Michael Kneba, Clemens Wendtner, MD, Wolfram Klapper, MD, Karl-Anton Kreuzer, Sebastian Böttcher, Stephan Stilgenbauer, Anna Maria Fink, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 4382.
DOI: https://doi.org/10.1182/blood.V128.22.4382.4382
Published: 2016
Journal Articles

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Julia von Tresckow, MD, Paula Cramer, MD, Jasmin Bahlo, Sandra Robrecht, Anja Engelke, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Thomas Illmer, MD, Holger Klaproth, MD, Sven Estenfelder, Matthias Ritgen, Kirsten Fischer, MD, Clemens-Martin Wendtner, MD, Karl-Anton Kreuzer, MD, Stephan Stilgenbauer, Sebastian Böttcher, Barbara Eichhorst, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 640.
DOI: https://doi.org/10.1182/blood.V128.22.640.640
Published: 2016
Journal Articles

Long-Term Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Chronic Lymphocytic Leukemia (CLL): 10-Year Follow-up of the Gcllsg CLL3X Trial

Isabelle Krämer, Stephan Stilgenbauer, Sascha Dietrich, Sebastian Böttcher, Matthias Ritgen, Donald Bunjes, Matthias Zeis, Michael Stadler, MD, Joerg Thomas Bittenbring, MD, Ute Hegenbart, Michael Hallek, Michael Kneba, Norbert Schmitz, MD, PhD, Hartmut Döhner, MD, Peter Dreger, MD
Journal: Blood
Blood (2016) 128 (22): 682.
DOI: https://doi.org/10.1182/blood.V128.22.682.682
Published: 2016